Aspen Neuroscience Inc

ASPEHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

13.82+1.01 (7.88%)

2026-11-12 00:54 CET

Market cap

372.50 USD m

Revenue, TTM

0.00 USD m

Net income, TTM

-19.07 USD m

Free cash flow, TTM

-18.02 USD m

EPS diluted, TTM

-0.66

P/E

Compare

Price

ASPE against its price

7.2% under the 52-week high of 14.90 on 30 Oct 2026. 52-week low 11.20 on 4 Nov 2026. Last 9 sessions, 33.0% high to low

Volume 0.62× normal · the line is the 50-bar volume average

Profile

ASPE

52-week range, 71% of the way up

11.2014.90

Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company, which engages in the development of autologous induced pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases. Its product candidate, sasineprocel, is an investigational single-dose, autologous iPSC-based cell therapy for the treatment of Parkinson's disease (PD). The company was founded by Jeanne F. Loring and Andres Bratt-Leal in 2018 and is headquartered in San Diego, CA.

Employees	117
IPO	Oct 30, 2026
ATR, 14d	1.97
Rel volume	0.62
Inst own	4.46%

Snapshot

6 groups

Valuation

Index	-
Market Cap	401.87M
Enterprise Value	678.07M
Income	-
Sales	-
Book/sh	-8.63
Cash/sh	2.49
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	117
IPO	Oct 30, 2026

Ratios

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	5.55
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	4.56
Current Ratio	4.56
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

Earnings

EPS (ttm)	-
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Ownership

Insider Own	-
Insider Trans	-
Inst Own	4.46%
Inst Trans	-
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	7.03%
SMA50	7.03%
SMA200	7.03%
Trades	-

Technical

Shs Outstand	29.08M
Shs Float	-
Short Float	-
Short Ratio	-
Short Interest	-
52W High	14.90 -7.25%
52W Low	11.20 23.39%
Volatility	13.08% -
ATR (14)	1.97
RSI (14)	-
Beta	-
Rel Volume	0.62
Avg Volume	465.68K
Volume	290,532

Performance

Perf Week	8.31%
Perf Month	-
Perf Quarter	-
Perf Half Y	-
Perf YTD	-5.99%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	12.81
Price	13.82
Change %	7.88%

Insider trading

5 filings

Insider	Relationship	Date	Transaction	Cost	Shares	Value	Total held	Form
Thompson Peter A.	Director	Nov 02 '26	Buy	15.00	1,000,000	15,000,000	3,589,132	Nov 04 06:47 PM
ORBIMED ADVISORS LLC	Director	Nov 02 '26	Buy	15.00	1,000,000	15,000,000	3,589,132	Nov 04 06:43 PM
ARCH Venture Fund X, L.P.	10% Owner	Nov 02 '26	Buy	15.00	1,200,000	18,000,000	1,200,000	Nov 02 09:50 PM
ARCH Venture Fund X, L.P.	10% Owner	Nov 02 '26	Buy	15.00	133,333	1,999,995	66,667	Nov 02 09:50 PM
ARCH Venture Partners XIV, L.P	10% Owner	Nov 02 '26	Buy	15.00	1,200,000	18,000,000	1,200,000	Nov 02 09:46 PM

Key figures

Revenue, TTM	0.00
Net income, TTM	-19.07
EPS diluted, TTM	-0.66
EBIT, TTM	-19.77
Free cash flow, TTM	-18.02
Gross margin	-%
Operating margin	-%
Net margin	-%
Market cap	372.50
P/E	-
Sales Y/Y, TTM	-

USD millions. TTM from the statement feed.

Quarterly earnings

actual against estimate

Period	Reported	EPS act	EPS est	EPS rep	Sales act	Sales est	Analysts
No quarterly earnings.

Period

Reported

EPS act

EPS est

EPS rep

Sales act

Sales est

Analysts

No quarterly earnings.

Annual earnings

Period	EPS act	EPS est	EPS rep	Sales act	Sales est
No annual earnings.

Period

EPS act

EPS est

EPS rep

Sales act

Sales est

No annual earnings.

Estimate revisions

last 14 periods

Period	Type	Date	Estimates	Up	Down	Mean	Low	High
No estimate revisions.

Period

Type

Date

Estimates

Down

Mean

Low

High

No estimate revisions.

Estimate history

Period	2024	2025
EPS, annual	-1.67	-2.134
EPS, quarterly	-0.563	-0.529	-0.601	-0.656
Period	Q1 '25	Q2 '25	Q1 '26	Q2 '26
Sales, annual	0	0
Period	2024	2025
Sales, quarterly	0	0	0	0
Period	Q1 '25	Q2 '25	Q1 '26	Q2 '26
Shares, annual	29.079	29.079	29.079
Period	2024	2025	MRQ
Shares, quarterly	29.079	29.079	29.079	29.079
Period	Q1 '25	Q2 '25	Q1 '26	Q2 '26

Income statement, annual

Currency USD, millions
Metric	TTM	2025FY	2024FY
Total Revenue	0.00	0.00	0.00
Cost of Goods Sold Incl. D&A	1.08	4.20	3.70
Gross Profit	-1.08	-4.20	-3.70
Selling, General and Administrative Excl. Other	18.69	55.10	49.76
Research and Development	14.41	40.35	34.53
Other Operating Expense	0.00	0.00	0.00
Operating Income	-19.77	-59.30	-53.46
Unusual Expense	0.00	0.00	0.00
Net Income Before Taxes	-19.07	-62.06	-48.56
Income Taxes	0.00	0.00	0.00
Consolidated Net Income	-19.07	-62.06	-48.56
Net Income From Continuing Operations	-19.07	-62.06	-48.56
Net Income	-19.07	-62.06	-48.56
EPS (Recurring)	-0.66	-2.13	-1.67
EPS (Basic, Before Extraordinaries)	-0.66	-2.13	-1.67
EPS (Diluted)	-0.66	-2.13	-1.67
EBITDA	-18.69	-55.10	-49.76
Non-Operating Income (Expense)	0.69	-2.75	4.90
Other After Tax Adjustments	0.00	0.00	0.00
Stock Option Compensation Expense	1.26	2.52	2.71
Shares Outstanding	29.08	29.08	29.08
Market Capitalization	372.50	372.50	-

Income statement, quarterly

Currency USD, millions
Metric	2026Q2	2026Q1	2025Q2	2025Q1
Total Revenue	0.00	0.00	0.00	0.00
Cost of Goods Sold Incl. D&A	1.08	1.04	0.98	0.96
Gross Profit	-1.08	-1.04	-0.98	-0.96
Selling, General and Administrative Excl. Other	18.69	17.41	13.74	15.20
Research and Development	14.41	13.28	10.06	10.13
Other Operating Expense	0.00	0.00	0.00	0.00
Operating Income	-19.77	-18.45	-14.72	-16.16
Unusual Expense	0.00	0.00	0.00	0.00
Net Income Before Taxes	-19.07	-17.47	-15.38	-16.37
Income Taxes	0.00	0.00	0.00	0.00
Consolidated Net Income	-19.07	-17.47	-15.38	-16.37
Net Income From Continuing Operations	-19.07	-17.47	-15.38	-16.37
Net Income	-19.07	-17.47	-15.38	-16.37
EPS (Recurring)	-0.66	-0.60	-0.53	-0.56
EPS (Basic, Before Extraordinaries)	-0.66	-0.60	-0.53	-0.56
EPS (Diluted)	-0.66	-0.60	-0.53	-0.56
EBITDA	-18.69	-17.41	-13.74	-15.20
Non-Operating Income (Expense)	0.69	0.98	-0.66	-0.21
Other After Tax Adjustments	0.00	0.00	0.00	0.00
Stock Option Compensation Expense	1.26	1.23	0.55	0.67
Shares Outstanding	29.08	29.08	29.08	29.08
Market Capitalization	372.50	-	-	-

Balance sheet, annual

Currency USD, millions
Metric	2025FY	2024FY
Cash & Short Term Investments	110.70	57.68
Short Term Receivables	0.00	0.00
Inventories	0.00	0.00
Other Current Assets	1.69	1.91
Total Current Assets	112.39	59.59
Net Property, Plant & Equipment	27.43	23.14
Total Investments and Advances	0.62	0.62
Long-Term Note Receivable	0.94	5.50
Other Assets	2.28	1.36
Total Assets	143.66	90.21
Short Term Debt Incl. Current Port. of LT Debt	3.53	3.43
Accounts Payable	2.64	0.85
Other Current Liabilities	8.09	9.76
Total Current Liabilities	14.26	14.04
Long Term Debt	346.48	233.88
Provision for Risks Charges	0.00	0.00
Other Liabilities	0.00	0.02
Total Liabilities	360.74	247.94
Non-Equity Reserves	0.00	0.00
Preferred Stock - Carrying Value	0.00	0.00
Common Equity	-217.08	-157.73
Total Shareholders Equity	-217.08	-157.73
Accumulated Minority Interest	0.00	0.00
Total Equity	-217.08	-157.73
Total Liabilities & Stockholders Equity	143.66	90.21
Book Value Per Share	-7.47	-5.42
Tangible Book Value Per Share	-7.47	-5.42
Full-Time Employees	117	-
Price to Book Ratio	-1.48	-
Return on Assets	-53.07	-
Return on Invested Capital	-47.96	-63.76
Quick Ratio	7.88	4.24
Current Ratio	7.88	4.24

Cash flow, annual

Currency USD, millions
Metric	TTM	2025FY	2024FY
Net Income	-19.07	-62.06	-48.56
Depreciation	1.08	3.96	3.51
Other Funds (Non Cash)	0.99	7.02	0.24
Funds from Operations	-17.01	-51.08	-44.80
Extraordinary Item	0.00	0.00	0.00
Changes in Working Capital	0.86	-1.76	0.63
Cash from Operating Activities	-16.15	-52.85	-44.17
Capital Expenditures	-1.87	-9.69	-2.58
Net Assets From Acquisitions	0.00	0.00	0.00
Sale of Fixed Assets and Businesses	0.00	0.00	0.00
Purchase or Sale of Investments	23.24	13.89	28.21
Purchase of Investments	-4.15	-33.61	-74.89
Sale Or Maturity of Investments	27.39	47.50	103.10
Other Uses	0.00	0.00	-5.00
Other Sources	0.00	0.00	0.00
Cash from Investing Activities	21.38	4.20	20.63
Cash Dividends Paid	0.00	0.00	0.00
Preferred Dividends (Cash Flow)	0.00	0.00	0.00
Change in Capital Stock	0.03	115.53	0.47
Repurchase of Common Pref Stock	0.00	0.00	0.00
Sale of Common Pref Stock	0.03	115.53	0.47
Proceedsfrom Stock Options	0.03	115.53	0.47
Issuance or Reduction of Debt, Net	0.00	0.00	0.00
Change in Long Term Debt	0.00	0.00	0.00
Issuance of Long Term Debt	0.00	0.00	0.00
Reduction of Long Term Debt	0.00	0.00	0.00
Net Financing Active Other Cash Flow	0.00	0.00	0.00
Other Financing Activities Uses	0.00	0.00	0.00
Cash from Financing Activities	-0.78	115.53	0.47
Net Change in Cash	4.45	66.88	-23.07
Free Cash Flow	-18.02	-62.54	-46.76
Deferred Taxes & Investment Tax Credit	-	0.00	0.00

Balance sheet, quarterly

Currency USD, millions
Metric	2026Q2	2026Q1	2025Q2	2025Q1
Cash & Short Term Investments	72.38	90.89	-	-
Short Term Receivables	0.00	0.00	-	-
Inventories	0.00	0.00	-	-
Other Current Assets	2.22	2.16	-	-
Total Current Assets	74.59	93.05	-	-
Net Property, Plant & Equipment	29.32	27.28	-	-
Total Investments and Advances	0.62	0.62	-	-
Other Assets	5.74	5.65	-	-
Total Assets	110.28	126.60	-	-
Short Term Debt Incl. Current Port. of LT Debt	3.58	3.56	-	-
Accounts Payable	5.54	5.30	-	-
Other Current Liabilities	7.23	5.28	-	-
Total Current Liabilities	16.35	14.14	-	-
Long Term Debt	345.00	345.75	-	-
Provision for Risks Charges	0.00	0.00	-	-
Other Liabilities	0.00	0.00	-	-
Total Liabilities	361.35	359.89	-	-
Non-Equity Reserves	0.00	0.00	-	-
Preferred Stock - Carrying Value	0.00	0.00	-	-
Common Equity	-251.07	-233.29	-	-
Total Shareholders Equity	-251.07	-233.29	-	-
Accumulated Minority Interest	0.00	0.00	-	-
Total Equity	-251.07	-233.29	-	-
Total Liabilities & Stockholders Equity	110.28	126.60	-	-
Book Value Per Share	-8.63	-8.02	-	-
Tangible Book Value Per Share	-8.63	-8.02	-	-
Price to Book Ratio	-1.48	-	-	-
Return on Invested Capital	-20.31	-15.54	-	-
Quick Ratio	4.56	6.58	-	-
Current Ratio	4.56	6.58	-	-

Cash flow, quarterly

Currency USD, millions
Metric	2026Q2	2026Q1	2025Q2	2025Q1
Net Income	-19.07	-17.47	-15.38	-16.37
Depreciation	1.08	1.04	0.98	0.96
Other Funds (Non Cash)	0.99	0.74	1.59	1.41
Funds from Operations	-17.01	-15.69	-12.81	-14.00
Extraordinary Item	0.00	0.00	0.00	0.00
Changes in Working Capital	0.86	-2.67	-1.50	-2.31
Cash from Operating Activities	-16.15	-18.36	-14.31	-16.31
Capital Expenditures	-1.87	-1.95	-2.55	-1.19
Net Assets From Acquisitions	0.00	0.00	0.00	0.00
Sale of Fixed Assets and Businesses	0.00	0.00	0.00	0.00
Purchase or Sale of Investments	23.24	-45.04	13.89	14.60
Purchase of Investments	-4.15	-51.42	-0.45	-9.37
Sale Or Maturity of Investments	27.39	6.38	14.34	23.97
Other Uses	0.00	0.00	0.00	0.00
Other Sources	0.00	0.00	0.00	0.00
Cash from Investing Activities	21.38	-46.99	11.35	13.41
Cash Dividends Paid	0.00	0.00	0.00	0.00
Preferred Dividends (Cash Flow)	0.00	0.00	0.00	0.00
Change in Capital Stock	0.03	0.09	0.01	0.04
Repurchase of Common Pref Stock	0.00	0.00	0.00	0.00
Sale of Common Pref Stock	0.03	0.09	0.01	0.04
Proceedsfrom Stock Options	0.03	0.09	0.01	0.04
Issuance or Reduction of Debt, Net	0.00	0.00	0.00	0.00
Change in Long Term Debt	0.00	0.00	0.00	0.00
Issuance of Long Term Debt	0.00	0.00	0.00	0.00
Reduction of Long Term Debt	0.00	0.00	0.00	0.00
Net Financing Active Other Cash Flow	0.00	0.00	0.00	0.00
Other Financing Activities Uses	0.00	0.00	0.00	0.00
Cash from Financing Activities	-0.78	0.09	0.01	0.04
Net Change in Cash	4.45	-65.25	-2.96	-2.85
Free Cash Flow	-18.02	-20.31	-16.86	-17.49

Revenue breakdown

Revenue split	-

Short interest

shares short against float, oldest to newest

Settlement	Of float	Shares short	Float	Avg volume
No short interest data.

Settlement

Of float

Shares short

Float

Avg volume

No short interest data.

Option chain

expiry 2026-11-11

Type	Strike	Bid	Ask	Last	IV	Open int	Volume	Delta	Theta	Vega
No option chain for this symbol.

Type

Strike

Bid

Ask

Last

Open int

Volume

Delta

Theta

Vega

No option chain for this symbol.

Latest SEC filings

Filed	Form	Description	Period	Link
2026-11-09	SCHEDULE 13G			SEC
2026-11-09	SCHEDULE 13D			SEC
2026-11-09	4	Statement of changes in beneficial ownership of securities	2026-11-05	SEC
2026-11-06	SCHEDULE 13G			SEC
2026-11-06	SCHEDULE 13D			SEC
2026-11-06	SCHEDULE 13G			SEC
2026-11-04	4	Statement of changes in beneficial ownership of securities	2026-11-02	SEC
2026-11-04	4	Statement of changes in beneficial ownership of securities	2026-11-02	SEC
2026-11-03	SCHEDULE 13G			SEC
2026-11-02	4	Statement of changes in beneficial ownership of securities	2026-11-02	SEC
2026-11-02	4	Statement of changes in beneficial ownership of securities	2026-11-02	SEC
2026-11-02	4	Statement of changes in beneficial ownership of securities	2026-11-02	SEC
2026-11-02	4	Statement of changes in beneficial ownership of securities	2026-11-02	SEC
2026-11-02	S-8	Initial registration statement for securities to be offered to employees pursuant to employee benefit plans		SEC
2026-11-02	8-K	Current report	2026-11-02	SEC
2026-10-30	424B4			SEC
2026-10-29	EFFECT	Effectiveness filing by commission order		SEC
2026-10-29	CERT			SEC
2026-10-29	3	Initial statement of beneficial ownership of securities	2026-10-29	SEC
2026-10-29	3	Initial statement of beneficial ownership of securities	2026-10-29	SEC
2026-10-29	3	Initial statement of beneficial ownership of securities	2026-10-29	SEC
2026-10-29	3	Initial statement of beneficial ownership of securities	2026-10-29	SEC
2026-10-29	3	Initial statement of beneficial ownership of securities	2026-10-29	SEC
2026-10-29	3	Initial statement of beneficial ownership of securities	2026-10-29	SEC
2026-10-29	3	Initial statement of beneficial ownership of securities	2026-10-29	SEC
2026-10-29	3	Initial statement of beneficial ownership of securities	2026-10-29	SEC
2026-10-29	3	Initial statement of beneficial ownership of securities	2026-10-29	SEC
2026-10-29	3	Initial statement of beneficial ownership of securities	2026-10-29	SEC
2026-10-29	3	Initial statement of beneficial ownership of securities	2026-10-29	SEC
2026-10-29	3	Initial statement of beneficial ownership of securities	2026-10-29	SEC

Insider activity by month

Month	Bought	Buys
2026-11	68.00M	5
2026-10	0	0
2026-09	0	0
2026-08	0	0
2026-07	0	0
2026-06	0	0
2026-05	0	0
2026-04	0	0
2026-03	0	0
2026-02	0	0
2026-01	0	0
2025-12	0	0
2025-11	0	0

Institutional holders

Manager	% owned
-

Manager

% owned

Funds

Fund	% owned
-

Fund

% owned

OakChart. ASPE. Cached 15 minutes.

Some panels did not load: ratings, news, si.